Browsing Tag
Granules India Limited
6 posts
Granules India (NSE: GRANULES) exits FDA audit with four observations as regulatory scrutiny intensifies
Granules India's Chantilly facility exits a routine US FDA cGMP audit with four procedural Form 483 observations and no data integrity findings. Read what it means for the GRANULES growth outlook.
Granules India completes Senn Chemicals acquisition to expand peptide therapeutics and CDMO services
Find out how Granules India is entering peptide therapeutics and CDMO services with its Swiss acquisition of Senn Chemicals.
Granules India gains key FDA approval for Unit V facility, marking major compliance milestone
Hyderabad-based Granules India Limited has achieved a significant regulatory milestone, securing an Establishment Inspection Report (EIR) with a…
Granules India subsidiary completes FDA PADE inspection with zero observations
Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of Granules India Limited, situated in Chantilly, Virginia, USA,…
FDA greenlights Granules India’s Metoprolol Succinate ER tablets
Granules India Limited announced its receipt of US Food and Drug Administration (FDA) approval for its Abbreviated New…
Granules pharmaceuticals gets six USFDA observations at Chantilly facility—what does it mean for its US growth plans?
Granules Pharmaceuticals gets six USFDA observations at its Chantilly, Virginia plant—what’s next for its US expansion strategy? Read the full analysis now.